Clinical-stage company developing new treatments for Dry Eye Disease. H+C was hired to bring the company out of stealth, update its brand, and support a number of corporate, clinical, and regulatory milestone.
Neotract develops innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. H+C was hired to position the company as a leading innovator for a common men’s condition, enlarged prostate.
H+C supported Auris through a number of important corporate milestones: coming out of stealth, fundraising, FDA clearance, launch of the Monarch Platform; and most recently the Johnson & Johnson acquisition of $3.4B – the largest medtech acquisition ever.